BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 16, 2015 | $770,000 | Replaced |
| 4th Quarter - Amendment | Jan 16, 2015 | $770,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RONALD MILLER | — |
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Copyright/Patent/Trademark CPT
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Trade (domestic/foreign) TRD
No bill, trade agreements and international intellectual property issues in India and Canada related to biopharmaceuticals. H.R. 3830 amend S. 1900, Bipartisan Congressional Trade Priorities Act, regarding all biopharmaceutical related provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Health Issues HCR
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RONALD MILLER | — |
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RONALD MILLER | — |
| LANE PENRY | — |
| CHRISTOPHER PERNIE | — |
| PAUL ANTHONY WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.